TARS (Tarsus Pharmaceuticals) Inventories, Work In Process: $1.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TARS Tarsus Pharmaceuticals Inc TARS
46 GF Score
Price $64.82
GF Value $160.53
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Tarsus Pharmaceuticals Inventories, Work In Process?

Tarsus Pharmaceuticals TARS -1.01% 46 Inventories, Work In Process is $1.4 Mil as of Jun. 2026. GuruFocus rates TARS with a GF Score™ of 46/100 and a GF Value™ of $160.53 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Tarsus Pharmaceuticals's work in process for the quarter that ended in Jun. 2026 was $1.4 Mil.

Tarsus Pharmaceuticals Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Tarsus Pharmaceuticals's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsus Pharmaceuticals Inventories, Work In Process Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial 0.00 0.00 0.39 0.61 1.41

Tarsus Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.00 1.41 1.63 1.36
TARS
46GF Score
Tarsus Pharmaceuticals Inc TARS
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsus Pharmaceuticals Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $1.4 Mil mean?
Tarsus Pharmaceuticals (TARS) has a Inventories, Work In Process of $1.4 Mil as of Jun. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' Inventories, Work In Process too high?
Tarsus Pharmaceuticals' current Inventories, Work In Process is $1.4 Mil. Overall, Tarsus Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Inventories, Work In Process compare to VERA and BEAM?
Tarsus Pharmaceuticals' Inventories, Work In Process of $1.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Inventories, Work In Process is $1.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $160.53, compared to a current price of $64.82 — trading 59.6% below its estimated fair value. The current Inventories, Work In Process is $1.4 Mil. Tarsus Pharmaceuticals' overall GF Score™ is 46/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Inventories, Work In Process is $1.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $64.82 is trading 59.6% below its estimated GF Value™ of $160.53. GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for TARS:

  • Inventories, Work In Process: $1.4 Mil
  • GF Value™: $160.53 vs. price of $64.82 (59.6% below fair value)
  • GF Score™: 46/100 with 1 warning sign

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
46GF Score

Get the complete analysis for TARS

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$64.82
Price
$160.53
GF Value